Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Olalekan O Oluwole, MD, MBBS, discusses the background and rationale of the research he contributed to, which was presented at the 2025 Transplantation & Cellular Therapy Meetings.

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...

Allogene Therapeutics (ALLO) announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Shares of US clinical-stage biotech Allogene Therapeutics rocketed 41% to $1.99 on Friday, as it announced the publication of ...

SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T therapies currently valued at approximately $299 million, has published new data ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with $63.6 billion in annual revenue and an impressive 74% gross profit margin, has announced the U.S. Food and Drug Administration's ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...